ClinicalTrials.gg
RecruitingNCT05527717RESCUE-SHOCKUpdated Nov 6, 2024

Revascularization Strategy of Multivessel Disease for Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Veno-arterial Extracorporeal Membrane Oxygenator

A Phase 4 interventional study of Culprit lesion only PCI and Immediate multi-vessel PCI in Cardiogenic Shock, Acute Myocardial Infarction and Multi Vessel Coronary Artery Disease, sponsored by Samsung Medical Center. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-11-06.

Sponsored by Samsung Medical Center · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
560
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Shock, Cardiogenic with a site in Korea, Republic of — 8 open to participants now, 8 under way, none of them phase 3. Shock, Cardiogenic · Korea, Republic of.

Planned enrollment
Largest of 10
560 · median 280
Started
2022
with 1 other
Phase 4
2 of 13
2 open now
Registered
6th of 13
by date
Lead sponsor
5 of 13
Samsung Medical Center

Among the 13 studies in Shock, Cardiogenic with a site in Korea, Republic of, this one has the largest planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2022, is one of 2 in phase 4, and was the 6th registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

8 of the 13 studies in Shock, Cardiogenic with a site in Korea, Republic of are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Shock, Cardiogenic with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study is a prospective, open-label, two-arm, randomized multicenter trial to identify whether immediate multi-vessel PCI would be better in clinical outcomes compared with culprit lesion-only PCI for AMI and multi-vessel disease with an advanced form of CS patients who require veno-arterial extracorporeal membrane oxygenator (VA-ECMO).

Read the detailed description

Cardiogenic shock (CS) is a fatal complication of acute myocardial infarction (AMI). Until now, in this setting, it has been well-known that early revascularization with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) was associated with improved clinical outcomes although the rate of mortality remains still high in the mechanical circulatory support (MCS) era. In real-world practice, since clinically significant non-infarct related artery (non-IRA) stenosis or occlusion in addition to an IRA can be found in 70% to 80% of patients with AMI complicated by CS, the decision of revascularization strategy is a crucial issue to improve clinical outcomes in CS patients with multivessel disease. The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) and the 2017 European Society of Cardiology (ESC) guidelines recommend considering PCI of severe stenosis in non-IRA during a primary procedure to improve overall myocardial perfusion and hemodynamic stability for patients with AMI and CS. However, the CULPRIT-SHOCK trial, which is the largest randomized trial in CS, demonstrated the 30-day risk of a composite of death or severe renal failure leading to renal-replacement therapy was higher in the immediate multi-vessel PCI than in the culprit lesion-only PCI group. In this regard, the recently updated guidelines do not recommend the routine non-IRA revascularization during primary PCI and it should be considered in selected cases in which there is a very severe flow-limiting non-IRA stenosis irrigating a large myocardial area. Nevertheless, there is still some unsolved issue regarding the role of non-IRA revascularization in AMI patients with CS. Majority of enrolled patients in the CULPRIT-SHOCK trial might have a mild form of CS (median systolic blood pressure of 100) and few patients received MCS devices (28.3% of study population). Furthermore, the mortality benefits of culprit-only PCI were attenuated at 1-year follow-up with an increased risk of repeat revascularization and hospitalization for heart failure. In contrast to the CULPRIT-SHOCK trial, the recent large United State registry from National Cardiovascular Data Registry demonstrated that the benefits of multi-vessel PCI in patients with non-ST-segment elevation MI and CS was more pronounced in those requiring MCS. In addition, recent data from the Korea Acute Myocardial Infarction National Health Registry showed that multivessel PCI was associated with a lower risk of all-cause death than culprit-only PCI, suggesting possible benefit of nonculprit lesion revascularization during the index hospitalization on long-term clinical outcomes.

Therefore, the current randomized trial sought to identify whether immediate multi-vessel PCI would be better in clinical outcomes compared with culprit lesion-only PCI for AMI and multi-vessel disease with advanced form of CS patients who requiring veno-arterial extracorporeal membrane oxygenator (VA-ECMO).

03

Conditions studied

  • Cardiogenic Shock
  • Acute Myocardial Infarction
  • Multi Vessel Coronary Artery Disease
  • Extracorporeal Membrane Oxygenation

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be at least 19 years of age
  • Patients presented with AMI (ST-segment elevation MI [STEMI] or non-ST-segment elevation MI [NSTEMI]) complicated by CS (SCAI Shock classification C, D or E) who requiring VA-ECMO.
  • Target lesions amenable for planned primary PCI by operators' decision
  • Patients with multi-vessel disease

Exclusion criteria

Exclusion Criteria:

  • Other causes of shock (hypovolemia, sepsis, obstructive shock).
  • Shock due to mechanical complication to MI (rupture of papillary muscle, the ventricular septum, or free wall).
  • Unwitnessed out of hospital cardiac arrest with persistent Glasgow coma scale \<8 after the return of spontaneous circulation.
  • Patients with single-vessel disease (Patients with single-vessel disease will be enrolled in the RESCUE-SHOCK registry)
  • Onset of shock >24 hours.
  • Known heparin intolerance.
  • Other severe concomitant disease with limited \< 6 months
  • Pregnancy or breast feeding
  • Do not resuscitate wish
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
560 participants (estimated)

Study arms

  • Active comparator
    Culprit-lesion only PCI arm

    Patients will receive culprit-lesion only PCI.

    Procedure: Culprit lesion only PCI

  • Experimental
    Immediate multi-vesesl PCI arm

    Patients will receive immediate multi-vessel PCI.

    Procedure: Immediate multi-vessel PCI

Interventions

  • ProcedureCulprit lesion only PCI

    Randomization will be done after coronary angiography before or during primary PCI for IRA. Patients will be randomized to either immediate multi-vesesl PCI group or culprit-lesion only PCI group with 1:1 ratio. This group will be taken culprit-lesion only PCI during primary PCI.

  • ProcedureImmediate multi-vessel PCI

    Randomization will be done after coronary angiography before or during primary PCI for IRA. Patients will be randomized to either immediate multi-vesesl PCI group or culprit-lesion only PCI group with 1:1 ratio. This group will be taken immediate multi-vesesl PCI during primary PCI.

06

What researchers measure

Primary outcomes

  1. Rates of all-cause mortality or advanced heart failure requiring cardiac replacement therapy

    all-cause mortality or requiring left ventricular assisted device (LVAD) insertion or heart transplantation)

    Time frame: 90 days after primary PCI

Secondary outcomes

  1. Rates of In-hospital mortality

    Death by any cause in hospital

    Time frame: Up to 30 days

  2. Rates of In-hospital cardiac mortality

    Death by cardiac cause in hospital

    Time frame: Up to 30 days

  3. Rates of VA-ECMO weaning success

    Successful weaning of VA-ECMO was defined as successful removal of VA-ECMO and not requiring further mechanical support because of recurring cardiogenic shock over the following 48 hours.

    Time frame: Up to 30 days

  4. Time to VA-ECMO weaning

    Time from VA-ECMO insertion to VA-ECMO weaning

    Time frame: Up to 30 days

  5. Rates of critical limb ischemia after successful VA-ECMO weaning

    Critical limb ischemia is defined as limb pain that occurs at rest, or impending limb loss that is caused by severe compromise of blood flow to the affected extremity. (Rutherford classification 4, 5, or 6)

    Time frame: Up to 30 days

  6. Cerebral Performance Category (CPC) 3-5 at discharge

    Neurologic performance scale at discharge

    Time frame: Up to 30 days

  7. Length of intensive-care unit (ICU) stay

    ICU stay day

    Time frame: Up to 30 days

  8. Total procedural time

    Procedural time (minutes)

    Time frame: Immediate after the index procedure

  9. Total amount of contrast use

    Contrast use (cc)

    Time frame: Immediate after the index procedure

  10. Rates of all-cause mortality

    Death by any cause

    Time frame: 90 Days and 12 months after primary PCI

  11. Rates of cardiac mortality

    Death by cardiac cause

    Time frame: 90 Days and 12 months after primary PCI

  12. Requirement of cardiac replacement therapy

    LVAD insertion or heart transplantation

    Time frame: 90 Days and 12 months after primary PCI

  13. Requirement of renal replacement therapy

    Continuous renal replacement therapy, hemodialysis, or peritoneal dialysis

    Time frame: 90 Days and 12 months after primary PCI

  14. Rates of myocardial infarction (MI)

    spontaneous MI during follow-up

    Time frame: 90 Days and 12 months after primary PCI

  15. Rates of MI related to culprit vessel

    MI related to culprit vessel during follow-up

    Time frame: 90 Days and 12 months after primary PCI

  16. Rates of MI related to non-culprit vessel

    MI related to non-culprit vessel during follow-up

    Time frame: 90 Days and 12 months after primary PCI

  17. Rates of stent thrombosis

    Academic Research Consortium (ARC)-defined definite or probable stent thrombosis

    Time frame: 90 Days and 12 months after primary PCI

  18. Rates of Re-hospitalization due to heart failure

    Re-hospitalization due to heart failure during follow-up

    Time frame: 90 Days and 12 months after primary PCI

  19. Rates of Re-hospitalization due to any cause

    Re-hospitalization due to any cause during follow-up

    Time frame: 90 Days and 12 months after primary PCI

  20. Rates of target-lesion revascularization (TLR)

    TLR during follow-up

    Time frame: 90 Days and 12 months after primary PCI

  21. Rates of target-vessel revascularization (TVR)

    TVR during follow-up

    Time frame: 90 Days and 12 months after primary PCI

  22. Rates of repeat revascularization

    Repeat revascularization during follow-up

    Time frame: 90 Days and 12 months after primary PCI

  23. Rates of cerebrovascular accident

    Cerebrovascular accident during follow-up

    Time frame: 90 Days and 12 months after primary PCI

  24. Rates of bleeding

    Bleeding ARC \[BARC\] type 2, 3, or 5

    Time frame: 90 Days and 12 months after primary PCI

  25. Rates of major bleeding

    (BARC type 3 or 5

    Time frame: 90 Days and 12 months after primary PCI

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2022 (actual). Primary completion is estimated for Dec 2027, 61 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2022
First posted
Sep 2, 2022
StartActual
Nov 16, 2022
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Nov 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05527717
Responsible party
Jeong Hoon Yang (Professor, Samsung Medical Center) — Principal investigator
First posted
Sep 2, 2022
Start date
Nov 16, 2022
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 6, 2024

Study contacts

Jeong Hoon Yang, MD
Contact
jhysmc@gmail.com
82-2-3410-3419
Ki Hong Choi, MD
Contact
cardiokh@gmail.com
82-2-3410-6653
Jeong Hoon Yang, MD
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion